Abliva AB publishes 2021 Annual report
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the English version ...
Press releases
Abliva AB Interim Report January – June 2021
Second quarter summary
Abliva AB publishes 2020 Annual report
Abliva AB (Nasdaq Stockholm: ABLI) today announced that the English version of the Annual report for 2020 is now available on the company’s website, www.abliva.com.
Abliva AB Interim Report January – June 2020
NeuroVive Pharmaceutical AB changes its name to Abliva AB - Two share issues bring a total of MSEK 87 to Abliva - Hadean Ventures new strategic owner
NeuroVive Pharmaceutical AB publishes 2019 Annual report
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) today announced that the English version of the Annual report for 2019 is now available on the company’s website, www.neurovive.com.
NeuroVive Pharmaceutical AB Interim Report January – June 2019
Focus on genetic mitochondrial diseases
NeuroVive Pharmaceutical AB Interim report January – June 2018
NeuroVive out-licenses targeted LHON therapy to BridgeBio
NeuroVive Pharmaceutical AB Interim report January – June 2017
Strategic in-licensing broadens the project portfolio
NeuroVive Pharmaceutical – Interim report January-June 2016
Business operations
NeuroVive share upgraded to OTC Markets Group – OTCQX Best Market in the US
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company's share has been upgraded to trading on the OTC Market Group's best market, OTCQX in the US. The ...
NeuroVive: Interim Report 1 Jan. 2016 to 31 Mar. 2016
Full speed ahead First Quarter (1 Jan. 2016 – 31 Mar. 2016)Net revenues were SEK 0 (0) and other operating income was SEK 46,000 (49,000).Loss before tax was SEK 10,916,000 (14,271,000).Earnings per s ...
Updated timeline for conversion of NeuroVive’s BTUs into shares and warrants
NeuroVive Pharmaceutical AB (publ) announces that registration of the preferential rights issue totaling SEK 94.4 m has now been completed, and provides an updated timeline for the conversion of Neuro ...